100 completed, 7 terminated, 5 unknown, 3 active not recruiting. 118 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 118 | Completed 100, Terminated 7, Unknown 5, Active not recruiting 3, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Ezetimibe: new trials by email Literature Review of Ezetimibe trials Research Report on Ezetimibe
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo - Lipidemia, Type 2 Diabetes (T2DM) | Phase 3 | Active not recruiting | NewAmsterdam Pharma | 300 | 2025-12-11 | 2026-09-09 |
| To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe - Hypertension, Primary Hypercholesterolaemia | Phase 3 | Enrolling by invitation | Hyundai Pharm | 125 | 2025-04-22 | 2025-05-22 |
| Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) Dapagliflozin 10mg Tab, Pitavastatin 4 Mg Oral Tablet, Rosuvastatin and Ezetimibe - HIV Infections, Weight Gain | Phase 3 | Active not recruiting | Kirby Institute | 300 | 2024-12-16 | 2026-07-22 |
| A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn) Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 301 | 2024-07-08 | 2026-03-27 |
| A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Placebo - Lipidemia, Coronary Artery Disease | Phase 3 | Active not recruiting | NewAmsterdam Pharma | 300 | 2024-05-16 | 2026-04-09 |
| Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis PCSK9 inhibitors and statins with or without ezetimibe, Statins with or without ezetimibe - Aortic Stenosis | Phase 3 | Recruiting | Beijing Anzhen Hospital | 160 | 2024-03-22 | 2024-05-09 |
| Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia | Phase 3 | Completed | NewAmsterdam Pharma | 407 | 2024-03-01 | 2025-10-08 |
| A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia Fimasartan, Ezetimibe/Atorvastatin, Fimasartan Placebo - Essential Hypertension, Primary Hypercholesterolemia | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 148 | 2023-07-13 | 2024-10-18 |
| Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. Inclisiran, Ezetimibe, Matching Placebo for Inclisiran - Hypercholesterolemia | Phase 3 | Completed | Novartis Pharmaceuticals | 350 | 2023-03-15 | 2025-10-16 |
| Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A Ezetimibe/Atorvastatin 10/5 mg, Atorvastatin 5mg, Ezetimibe 10mg - Hypercholesterolemia, Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 252 | 2022-08-17 | 2023-08-01 |
| Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol Amlodipine, Ezetimibe/Rosuvastatin, Ezetimibe/Rosuvastatin Placebo - Hypertension, Hypercholesterolemia | Phase 3 | Completed | Celltrion Pharm, Inc. | 163 | 2022-08-05 | 2026-05-08 |
| A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A AD-221, AD-221A, AD-221B - Primary Hypercholesterolemia | Phase 3 | Completed | Addpharma Inc. | 290 | 2021-11-16 | 2022-07-20 |
| Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Ezetimibe 10mg, Placebo - Diabetes Mellitus, Type 2, Diabetic Kidney Disease | Phase 3 | Unknown | Steno Diabetes Center Copenhagen | 60 | 2020-10-01 | 2022-01-18 |
| Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Pitavastatin, Ezetimibe, 1PC111 - Primary Hypercholesterolemia, Mixed Dyslipidemias | Phase 3 | Completed | Orient Pharma Co., Ltd. | 390 | 2020-08-01 | 2022-05-18 |
| Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study) Rosuvastatin 40mg - Coronary Artery Disease | Phase 3 | Unknown | Bjarne Linde Noergaard | 120 | 2020-05-13 | 2021-02-05 |
| Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine Ezetimibe/Rosuvastatin, Telmisartan, Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET - Hypercholesterolemia, Hypertension | Phase 3 | Completed | Addpharma Inc. | 131 | 2020-01-23 | 2021-05-12 |
| Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451 Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug), Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug), Amlodipine/Olmesartan 10/40mg (Combination drug) - Hypertension, Dyslipidemia | Phase 3 | Unknown | Daewoong Pharmaceutical Co. LTD. | 237 | 2019-11-20 | 2019-11-13 |
| A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia HCP1701, Losartan, Amlodipine - Hypertension, Dyslipidemias | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 145 | 2019-07-16 | 2020-11-30 |
| To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia Livalo, Ezetrol - Primary Hypercholesterolemia | Phase 3 | Completed | JW Pharmaceutical | 283 | 2019-06-11 | 2021-12-01 |
Showing 20 of 118. Sign in to see all of them.
Hypercholesterolemia (81) · Hyperlipidemias (12) · Atherosclerosis (10) · Coronary Disease (10) · Dyslipidemias (7) · Coronary Artery Disease (6) · Diabetes Mellitus, Type 2 (6) · Hyperlipoproteinemia Type II (6) · Hypertension (6) · Heart Diseases (4) · Lipid Metabolism, Inborn Errors (3) · Essential Hypertension (2) · Hypertriglyceridemia (2) · Metabolic Syndrome (2) · Sitosterolemia (2)
Organon and Co (58) · Amgen (6) · Sanofi (6) · Addpharma Inc. (3) · NewAmsterdam Pharma (3) · Regeneron Pharmaceuticals (3) · Abbott (2) · AstraZeneca (2) · Eli Lilly and Company (2) · Esperion Therapeutics, Inc. (2) · IlDong Pharmaceutical Co Ltd (2) · Merck Sharp & Dohme LLC (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Alvogen Korea (1) · Beijing Anzhen Hospital (1)
United States (23) · South Korea (17) · Canada (16) · France (12) · Denmark (11) · Spain (10) · Australia (9) · Germany (9) · Italy (8) · Netherlands (8) · South Africa (8) · Belgium (7) · United Kingdom (7) · Czechia (6) · Hungary (6)
Hyo Soo Kim, M.D., Ph.D (2) · Ron Haberman, MD (2) · Bjarne L Noergaard, MD, PhD (1) · Christie M Ballantyne, MD FACP FACC (1) · Christine Ballantyne, MD (1) · Francisco Fonseca, physician (1) · Frederick F Samaha, M.D. (1) · Gail Matthews, MD (1)
PMID 27777279, PMID 30183102, PMID 34298554, PMID 22087637, PMID 25269777, PMID 25431239, PMID 12034651, PMID 12423708, PMID 12719279, PMID 15311720, PMID 15389231, PMID 15811480, PMID 17985033, PMID 18376000, PMID 18376001, PMID 18765432, PMID 18940534, PMID 19059567, PMID 19061694, PMID 19331437, PMID 19380898, PMID 20151997, PMID 20185012, PMID 20435205, PMID 20492655, PMID 20599002, PMID 20663203, PMID 20934572, PMID 21029821, PMID 21118495, PMID 21518985, PMID 21596364, PMID 22293030, PMID 23040830, PMID 24063830, PMID 24411003, PMID 25037695, PMID 25606700, PMID 25687353, PMID 25841542, PMID 25985907, PMID 26030325, PMID 26330412, PMID 26638010, PMID 26687696, PMID 26821621, PMID 27039291, PMID 28231942, PMID 28291866, PMID 28412650
2017 (2), 2004 (1), 2005 (1), 2008 (1), 2009 (1), 2015 (1), 2023 (1), 2025 (1)